Urinary Tract Infection Testing Market To Reach $1.9 Billion By 2033

Urinary Tract Infection Testing Market Growth & Trends

The global urinary tract infection testing market size is expected to reach USD 1.9 billion by 2033, registering a CAGR of 5.9% from 2026 to 2033, according to a new report by Grand View Research, Inc. The urinary tract infection (UTI) testing market is witnessing growth due to factors such as rising disease burden, increasing geriatric population, rapid technological advancements, and high R&D investments by key players to introduce novel & innovative products, such as self-testing & rapid Point-of-Care (PoC) devices products.

Urinary tract infection is becoming a common global concern. According to research studies, UTI occurs in one in five adult women at some point in their life. In the U.S., about 25%-40% of women aged 20-40 have suffered a UTI. In the U.S., about 250,000 cases of pyelonephritis are reported every year. In women aged 18-19, its incidence is about 28/10,000, out of which 7% of cases require hospital admission. Genetic and cultural factors may influence its prevalence; for instance, in South Korea, the incidence of pyelonephritis is around 59/10,000. Its recurrence is more common than other UTIs, with the recurrence rate being 5.7% in men and 9% in women.

Patients with diabetes are at increased risk of developing urinary tract infections such as acute cystitis, and therefore, the increasing global prevalence of diabetes is likely to contribute to cystitis growth. According to an NCBI article, type 2 diabetes raises UTI risk and patients with type 2 diabetes experience frequent & severe UTIs. According to the International Diabetes Federation (IDF) data from 2021, approximately 643 million individuals will have diabetes by 2030 and 783 million by 2045. Moreover, the estimated prevalence of asymptomatic bacteriuria in diabetic females is 26%, compared to 6% in nondiabetic females. Such factors are expected to boost the prevalence of cystitis globally.

However, due to the rise in awareness about such diseases, the demand for specialist treatment has increased in recent years. According to the U.S. Department of Health and Human Services, in the U.S., the number of practicing urologists in 2020 was 4.07 per 100,000 populations. The report further stated that due to the rise in demand, a shortage of urologists was observed, which is likely to exceed nearly 3,600 physicians by 2025. This can impede market growth in the coming years. Moreover, COVID-19 has had a detrimental impact on the industry. Individuals with UTIs have experienced substantial disruptions in testing and emergency care.

Key players are introducing novel products to strengthen their portfolios. For instance, in September 2021, OpGen, Inc. announced initiating clinical trials of the Unyvero Urinary Tract Infection Panel. The panel can analyze a broad range of pathogens and antimicrobial resistance markers directly from a urine sample. Successful clinical trials and the launch of such technologically advanced & efficient products are anticipated to drive market growth over the coming years. Similarly, in July 2020, Uqora, Inc. (Pharmavite, LLC), a urinary health biotechnology company, launched a UTI diagnostic and management kit. The kit includes a rapid UTI diagnostic device, Clarify, compatible with a PoC and homecare setting.

 Request a free sample copy or view report summary: Urinary Tract Infection Testing Market Report

Urinary Tract Infection Testing Market Highlights

• By testing method, Culture segment led the market with the largest revenue share of 54.7% in 2025.

• By type, Cystitis segment led the market with the largest revenue share of 69.0% in 2025. The pyelonephritis segment is expected to grow at the fastest CAGR of 6.7% over the forecast period.

• By product, Consumables segment led the market with the largest revenue share of 71.0% in 2025. The software and services segment is expected to grow at the fastest CAGR of 6.9% over the forecast period.

• By end-use, Hospital Laboratories segment led the market with the largest revenue share of 39.6% in 2025. The diagnostic and reference laboratories segment is expected to grow at the fastest CAGR over the forecast period.

• North America dominated the global urinary tract infection testing market and accounted for the largest revenue share of 38.6% in 2025. The U.S. accounted for the largest share of the North America urinary tract infection testing market.

Urinary Tract Infection Testing Market Segmentation

Grand View Research has segmented global urinary tract infection testing market report on the basis of testing method, type, product, end-use, and region:

Urinary Tract Infection Testing Testing Method Outlook (Revenue, USD Million, 2021 - 2033)

• Culture

• Antimicrobial Resistance (AMR) Testing

• PCR Testing

• Other Diagnostic Methods (dipstick testing, automated urine analyzers)

Urinary Tract Infection Testing Type Outlook (Revenue, USD Million, 2021 - 2033)

• Urethritis

• Cystitis

• Pyelonephritis

Urinary Tract Infection Testing Product Outlook (Revenue, USD Million, 2021 - 2033)

• Instruments

• Consumables

• Software and Services

Urinary Tract Infection Testing End-use Outlook (Revenue, USD Million, 2021 - 2033)

• Urology Centers/Clinics

• Hospital Laboratories

• Diagnostic and Reference Laboratories

• Emergency Departments

• Urgent Care Centers

• Others

Urinary Tract Infection Testing Regional Outlook (Revenue, USD Million 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Denmark

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Urinary Tract Infection Testing Market

• bioMérieux SA

• Thermo Fisher Scientific Inc.

• Bio-Rad Laboratories, Inc.

• Bruker Corporation

• Beckman Coulter, Inc.

• F. Hoffmann-La Roche Ltd

• Siemens Healthineers AG

• Sysmex Corporation

• 3B BlackBio Dx Limited

• Seegene Inc.